Prometheus Biosciences, Inc. Common Stock
RXDX
RXDX was delisted on the 15th of June, 2023.
116 hedge funds and large institutions have $870M invested in Prometheus Biosciences, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 35 increasing their positions, 36 reducing their positions, and 16 closing their positions.
94% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 16
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
13% more funds holding
Funds holding: 103 → 116 (+13)
3% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 36
17% less capital invested
Capital invested by funds: $1.04B → $870M (-$175M)
90% less call options, than puts
Call options by funds: $1.36M | Put options by funds: $13.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$38.2M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$21.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$18.4M |
| 4 |
RI
RTW Investments
New York
|
+$12.5M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$11.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$22M |
| 2 |
State Street
Boston,
Massachusetts
|
-$14.6M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$11.6M |
| 4 |
BlackRock
New York
|
-$9.97M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$9.25M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
126
Virtu Financial
New York
| – | -$201K | -5,311 | Closed |
|
|
PFS
127
Prospera Financial Services
Dallas,
Texas
| – | -$156K | -4,125 | Closed |
|
|
DFCM
128
Dark Forest Capital Management
San Juan,
Puerto Rico
| – | -$13K | -353 | Closed |
|
|
TWA
129
TCI Wealth Advisors
Tucson,
Arizona
| – | -$5K | -133 | Closed |
|
|
C
130
Covestor
London,
United Kingdom
| – | -$58 | -2 | -22% |
|
131
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | +$203 | +7 | New |
|
|
EI
132
Ellevest Inc
New York
| – | +$348 | +12 | New |
|
RXDX Hedge Fund Activity: Q2 2022 in Review
116 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Prometheus Biosciences, Inc. Common Stock (RXDX) for Q2 2022, worth a combined $870M — down 17% from $1.04B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new RXDX positions and 16 closed out — a net gain of 15 holders — while 35 added to existing stakes and 36 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $38.2M. The largest seller was Perceptive Advisors, cutting an estimated $22M.
- 116 institutional investors held Prometheus Biosciences, Inc. Common Stock (RXDX) as of Q2 2022, up from 103 in Q1 2022.
- Funds reported $870M of Prometheus Biosciences, Inc. Common Stock stock for Q2 2022, down 17% quarter-over-quarter.
- 31 funds opened new Prometheus Biosciences, Inc. Common Stock positions in Q2 2022 and 16 closed out, a net change of +15 holders.
- The largest Prometheus Biosciences, Inc. Common Stock buyer in Q2 2022 was Point72 Asset Management, an estimated $38.2M added.
- The largest Prometheus Biosciences, Inc. Common Stock seller in Q2 2022 was Perceptive Advisors, an estimated $22M sold.
Based on aggregated 13F filings for Q2 2022.